Search
Donislecel
go.drugbank.com/drugs/DB17961Approved[L47196] Donislecel was approved by the FDA on June 28, 2023, and is available under the brand name LANTIDRA from CellTrans Inc.[L47196] … L47196] Donislecel is particularly beneficial for type 1 diabetic patients with hypoglycemia unawareness, the inability to detect blood glucose dropping and thus unable to prevent further hypoglycemia, by
Dalfopristin
go.drugbank.com/drugs/DB01764ApprovedDalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.
Interferon alfa-2b
go.drugbank.com/drugs/DB00105ApprovedInvestigationalThis protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Rilapladib
go.drugbank.com/drugs/DB05119InvestigationalRilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2...
Cannabidivarin
go.drugbank.com/drugs/DB14050InvestigationalCompared to its homolog, [DB09061], CBDV is shortened by two methyl (CH2) groups on its side chain. … In October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome [L2952] and again in February 2018 for treatment of Fragile X Syndrome [L2951].
Temafloxacin
go.drugbank.com/drugs/DB01405ApprovedWithdrawnIt was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three
Protriptyline
go.drugbank.com/drugs/DB00344ApprovedIn non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood.
Tasimelteon
go.drugbank.com/drugs/DB09071ApprovedInvestigationalBy activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism … Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Alirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of